Neoadjuvant chemotherapy has proven clinical benefit in mMuscle- invasive bladder cancer. Cisplatin is the likely driver of this benefit. Textbook definitions of cisplatin ineligibility may restrict almost 50% of patients from therapy.
Checkpoint inhibitors (anti- PD-1 antibodies and anti- CTLA-4 antibodies) are currently in clinical trials for neoadjuvant use. Initial data from these studies appear promising.
European urology focus. 2019 Nov 18 [Epub ahead of print]
Arnab Basu, Sarmad Sadeghi
Department of Hematology & Medical Oncology, University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, AL, USA. Electronic address: ., Department of Hematology & Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/31753690